Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys

Toxicological Sciences

Volumn 44, Issue 2, 1998, Pages 97-106

  Lacy, Steven A ^a,c   Hitchcock, Michael J M ^a   Lee, William A ^a   Tellier, Pierre ^b   Cundy, Kenneth C ^a  

^a GILEAD SCIENCES   (United States)

^b Canada Bio Research Laboratoires Ltd   (Canada)

^c PHARMACYCLICS INC   (United States)

Author keywords

1 (S) 3 hydroxy 2 phosphonomethoxy)propyl cytosine; Biological activity; Cidofovir; Cidofovir injection (Vistide); Nucleotide analogue with antiherpesvirus activity

Indexed keywords

CIDOFOVIR; PROBENECID;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; MONKEY; NEPHROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION;

ANIMALIA; MACACA FASCICULARIS;

EID: 0031716603     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1006/toxs.1998.2481     Document Type: Article

References (21)

1. Berndt, W. O. (1983). Transport of citrinin by rat renal cortex. Arch. Toxicol. 54, 35-40.
2. Berndt, W. O. (1989). Potential involvement of renal transport mechanisms in nephrotoxicity. Toxicol. Lett. 46, 77-82.
3. Bischofberger, N., Hitchcock, M. J. M., Chen, M. S., Cundy, K. C., Barkhimer, D., Kent, K. M., Lacy, S. A., Lee, W. A., Li, Z.-H., Louie, M., Mendel, D. B., Smee, D. S., and Smith, J. L. (1994). Cyclic HPMPC: An intracellular prodrug for HPMPC with improved therapeutic index in vivo. Antimicrob. Agents Chemother. 38, 2387-2391.
4. Cihlar, T., Votruba, I., Horska, K., Liboska, R., Rosenberg, I., and Holy, A. (1992). Metabolism of 1-(S)-(3-hydroxy-2-phosphonomethoxy propyl)-cytosine (HPMPC) in human embryonic lung cells. Collect. Czech. Chem. Commun. 57, 661-672.
5. Cundy, K. C., Li, Z.-H., and Lee, W. A. (1994). Effect of concomitant probenecid on the tissue distribution and urinary excretion of HPMPC in preclinical models. Pharm. Res. 11(Suppl.), S449.
6. Cundy, K. C., Petty, B. G., Flaherty, J., Fisher, P. E., Polis, M. A., Wachsman, M., Lietman, P. S., Lalezari, J. P., Hitchcock, M. J. M., and Jaffe, H. S. (1995). Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 39, 1247-1252.
7. Cundy, K. C., Li, Z.-H., Hitchcock, M. J. M., and Lee, W. A. (1996a). Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug. Drug Metab. Dispos. 24, 738-744.
8. Cundy, K. C., Li, Z.-H., and Lee, W. A. (1996b). Effect of probenecid on the distribution, metabolism, and excretion of cidofovir in rabbits. Drug Metab. Dispos. 24, 315-321.
9. Cundy, K. C., Bidgood, A., M., Lynch, G., Shaw, J.-P., Griffin, L., and Lee, W. A. (1996c). Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. Drug Metab. Dispos. 24, 745-752.
10. Cunningham, R. F., Israili, Z. H., and Dayton, P. G. (1981). Clinical pharmacokinetics of probenecid. Clin. Pharmacokinet. 6, 135-151.
11. Hitchcock, M. J. M., Jaffe, H. S., Martin, J. C. and Stagg, R. J. (1996). Cidofovir, a new agent with potent anti-herpes activity. Antiviral Chem. Chemother. 7, 115-127.
12. Ho, H.-T., Woods, K. L., Bronson, J. J., De Boeck, H., Martin, J. C., and Hitchcock, M. J. M. (1992). Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Mol. Pharmacol. 41, 197-202.
13. Lalezari, J. P., Drew, W. L., Glutzer, E., James, C., Miner, D., Flaherty, J., Fisher, P. E., Cundy, K., Hannigan, J., Martin, J. C, and Jaffe, H. S. (1995). (S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl] cytosine (Cidofovir): Results of a phase I/II study of a novel antiviral nucleotide analogue. J. Infect. Dis. 171, 788-796.
14. Lalezari, J. P., Stagg, R. J., Kupperman, B. D., Holland, G. N., Kramer, F., Ives, D. V., Youle, M., Robinson, M. R., Drew, W. L., and Jaffe, H. S. (1997). Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS: A randomized, controlled trial. Ann. Intern. Med. 126, 257-263.
15. Lu, R., Kanai, N., Bao, Y., Wolkoff, A. W., and Schuster, V. L. (1996). Regulation of renal oatp mRNA expression by testosterone. Am. J. Physiol. 270, F332-337.
16. Naesens, L., Snoeck, R., Andrei, G., Balzarini, J., Neyts, J., and De Clercq, E, (1997). HPMPC (cidofovir), PMEA (adefovir). and related acyclic nucleoside phosphonate analogues: A review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chem. Chemother. 8, 1-23.
17. Studies of Ocular Complication of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group (SOCA) (1997). Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. Ann. Intern. Med. 126, 264-274.
18. Tune, B. N. (1993). The nephrotoxicity of β-lactam antibiotics. In Toxicology of the Kidney (J. B. Hook and R. S. Goldstein, Eds.), 2nd ed., pp. 257-281. Raven Press, New York.
19. Tune, B. M., and Flavert, D. (1980a). Cephalosporin nephrotoxicity: Transport, cytotoxicity and mitochondrial toxicity of cephaloglycin. J. Pharmacol. Exp. Ther. 215, 186-190.
20. Tune, B. M., and Flavert, D. (1980b). Mechanisms of cephalosporin nephrotoxicity: A comparison of cephaloridine and cephaloglycin. Kidney Int. 18, 591-600.
21. Vlasses, P. H., Holbrook, A. M., Schrogie, J. J., Rogers, J. D., Ferguson, R. K., and Abrams, W. B. (1980). Effect of orally administered probenecid on the pharmacokinetics of cefoxitin. Antimicrob. Agents Chemother. 17, 847-855.